Slingshot members are tracking this event:

Gilead (GILD) Plans to Submit Marketing Authorization Application (MAA) to European Commission for Bictegravir (B/F/TAF) Single Tablet HIV-1 Infection Regimen in Q3 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Marketing Authorization Application, Maa, European Commission, Bictegravir, B/f/taf, Single Tablet, Hiv-1 Infection, Emtricitabine, Tenofovir Alafenamide